Shares of agilon health, Inc. (NYSE: AGL) fell more than 25% in after-hours trading on Monday, August 4, 2025, after the company announced that its CEO, president and director, Steven Sell, had stepped down effective immediately and that it was withdrawing its full-year 2025 financial guidance. The company attributed the move to unexpected medical cost pressures and downward adjustments to prior revenue estimates.
The complaint alleges that, throughout the Class Period: (1) agilon recklessly issued guidance for 2025 that they knew or should have known was not going to be achieved, given material industry headwinds of which they were aware; (2) agilon materially overstated the immediate positive financial impact from strategic actions taken by agilon to reduce risk; and (3) as a result, statements about agilon’s business, operations, and prospects were materially false and/or misleading at all times.
Contact our attorneys for a no-cost case evaluation.